In recent times we’re witnessing a proper boom in weight loss medication. Even though there are a lot of viable, FDA-approved options, scientists continue to work on new, more effective and less harmful ones.
When it comes to weight loss and diabetes battling peptides, first came semaglutide. Semaglutide was the undisputed champion promoting both weight loss, blood sugar control and cardiovascular health.
Shortly after, along came tirzepatide which proved to be even more effective than semaglutide. A gigantic human test subject study, involving 18,386 individuals, overwhelmingly showed that out of those treated with tirzepatide, 85% experienced a weight loss of 5% and greater. While the semaglutide group had “only” 66.5%.
But, our story doesn’t end there! Lately, there’s been more and more talk about retatrutide, some even deeming it as “a triumph over obesity,” and cagrisema said to be even more effective than retatrutide. But is it really so?
How do these three compare between each other, what did the studies show us, is there any truth to these claims?
We’re going to answer all of these, and more, in today’s post, so stay tuned.
Tirzepatide – Overview
Tirzepatide is one of the latest FDA-approved type 2 diabetes treatments. Numerous clinical studies demonstrated its effectiveness in weight loss, improved glycemic control and an overall weight reduction in patients. Of course, every peptide sold on our website is for research purposes only.
The one being prescribed to patients is sold under the brand names Mounjaro and Zepbound, licenced and sold under Eli Lilly and Company, its subsidiaries or affiliates.
Retatrutide – Overview
Retatrutide is a new incretin mimetic agent – a gut derived peptide secreted after food intake, which stimulates insulin secretion and hyperglycaemia. Many different animal studies proved it leads to a significant weight loss in test subjects, even greater than that of tirzepatide.
There was also a double-blind study involving obese and overweight patients divided into two groups – retatrutide and placebo. After 48 weeks, the results showed that 60-100% of all treated patients experienced weight loss, 72% achieved normoglycemia, and only 13 individuals (out of 338) experienced any significant side effects.
Cagrisema Overview
Developed by Novo Nordisk, cagrisema is actually a combination of GLP-1 receptor agonist medication and cagrilintide. Together with insulin, cagrisema successfully suppresses hunger, makes people feel full longer and might even prove to be a long-term solution for people with diabetes 2.
Even though its based on semaglutide (adopting GLP-1 receptor agonist role), clinical studies showed its much more effective – patient’s average decrease in body fat was 15.6% while on cagrisema, and “only” 5.1% on semaglutide.
Tirzepatide VS Retratutide VS Cagrisema – Effectiveness
The main difference between tirzepatide and retatrutide is in their structure:
- Tirzeaptide – this peptide is a combination of as much as three active components – liraglutide, GLP-1 agonist and oxyntomodulin analogue
- Retratutide – while retratutide is composed of only one active component called exenatide
- Cagrisema – cagrisema is a combination of GLP-1 receptor agonist and cagrilintide
Of course, these drugs offer similar effects – managing diabetes, increasing insulin production and lowering blood glucose.
But, as we’ve seen in the recent studies, retatrutide has been shown to reduce appetite more effectively than tirzepatide; also being able to manage hunger and the feeling of fullness better. And patients using cagrisema experienced an even greater loss due to the drug’s ability to suppress appetite further.
Studies also showed their effectiveness in:
- HbA1c levels – retatrutide and cagrisema had better results in lowering the HbA1c, primary indicator of diabetes
- Safety – retatrutide and cagrisema are generally better tolerated, as compared to tirzepatide, and does not increase the risk of hypoglycemia (or weight gain) as some other medication would. They are also less aggressive to the application site, making the process of administration more manageable for the patient.
So, judging by the clinical results we have thus far, both retratutide and cagrisema are a more superior option for managing diabetes, and getting a firm grip on weight control in obese individuals.
Our support team is at your service, ensuring customer satisfaction.
